Skip to content

Study on the clinical effecy and mechanism of KaiyuTongzhi method in treating metabolic syndrome

Study on the clinical effecy and mechanism of KaiyuTongzhi method in treating metabolic syndrome

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2022000029
Enrollment
Unknown
Registered
2022-06-20
Start date
2022-07-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

metabolic syndrome

Interventions

Treatment Group:Kaiyutongzhi method of massage and basic therapy

Sponsors

Guang'anmen Hosptial
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: (1) Age 18-60 years old, gender is not limited; (2) Central obesity: waist circumference male = 90cm, female = 85cm; (3) Hyperglycemia: fasting blood glucose = 6.1 mmol/L or 2 h after sugar load blood glucose = 7.8 mmol/L and/or those who have been diagnosed with diabetes and treated; (4) Hypertension: blood pressure = 130/85 mmHg (1 mmHg = 0.133 kPa) and /or has been confirmed as hypertension and treated; (5) Fasting triglycerides (TG) = 1.70 mmol/L; (6) Fasting HDL cholesterol (HDL-C) < 1.04 mmol/L; (7) The TCM syndrome classification are hepatic depression stagnation and syndrome of intermingled phlegm and blood stasis. (3)(4)(5)(6) is diagnostic with two or more items.

Exclusion criteria

Exclusion criteria: (1) Patients with serious complications of type 2 diabetes mellitus (such as diabetic nephropathy, diabetic foot, diabetic ketoacidosis, etc.); (2) Patients with severe primary diseases such as uncontrolled hypertension, myocardial infarction, coronary atherosclerosis, cerebral infarction, infectious liver disease, kidney failure, glomerulonephritis and so on; (3) Patients who are suspicious or have been clearly diagnosed with skin problems, soft tissue injuries, osteoarthropathy, gastrointestinal diseases, blood diseases with bleeding tendencies, etc. that are not suitable for manual treatment; (4) Pregnant and lactation patients; (5) Those who have a serious gastrointestinal reaction after taking metformin and cannot continue to take the drug; (6) Patients with mental illness, cognitive dysfunction, inability to cooperate with doctors; (7) Easy to lose visit, such as frequent changes in the working environment; (8) Patients who are participating in other clinical trials.

Design outcomes

Primary

MeasureTime frame
Waist circumference;

Secondary

MeasureTime frame
Waist-Hip Ratio;TLR4mRNA;hs-CRP;Liver ultrasound;Visceral aliphatic factor;Blood sugar;Visceral fat;HOMA-IR;Index of ß-cell function in HOMA;IL-6;TLR4;Blood pressure;NF-?B p65;NF-?B p65mRNA;TNF-a;Blood lipid;Insulin;

Countries

China

Contacts

Public ContactLijun Wang
109001899@qq.com13810575557

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026